Skip Navigation

JNCI Journal of the National Cancer Institute 1998 90(19):1428-1430; doi:10.1093/jnci/90.19.1428
© 1998 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Reynolds, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Reynolds, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Tamoxifen Debate Hinges on Whose Risk is High Enough

Tamoxifen moved another step closer to approval for breast cancer prevention when the Oncologic Drugs Advisory Committee of the Food and Drug Administration on Sept. 2 recommended approval of its use to reduce the risk of breast cancer in women at high risk for the disease.

But questions remain about whose risk is high enough to outweigh the risk of potential side effects. So far, physicians appear cautious about prescribing tamoxifen to healthy women. And new findings heralding the preventive potential of a rival drug, raloxifene, complicate the picture.

After release of the Breast Cancer Prevention Trial results, first announced in April and published Sept. 16, showing a 49% . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann Fam MedHome page
R. Taylor and K. Taguchi
Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump
Ann. Fam. Med, May 1, 2005; 3(3): 242 - 247.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. J. Powles
Re: Tamoxifen for Prevention of Breast Cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
J Natl Cancer Inst, April 21, 1999; 91(8): 730 - 730.
[Full Text] [PDF]